Search
peginesatide (Omontys)
Indications:
- treatment of anemia in dialysis patients
Dosage:
- once a month administration
Adverse effects:
- > 10%
- arthralgia, diarrhea, hypertension, vomiting
- higher risk of cardiovascular events (RR = 1.32) & mortality than darbepoetin in patients with chronic renal failure NOT on dialysis [2]
- adverse effects similar to epoietin-alpha in patients on dialysis [2]
Mechanism of action:
- stimulates erythropoiesis (non-inferior to epoietin-alpha or darbepoetin) [2]
Interactions
drug adverse effects of erythropoiesis-stimulating agents
General
erythropoiesis-stimulating agent
References
- FDA NEWS RELEASE: March 27, 2012
FDA approves Omontys to treat anemia in adult patients on dialysis
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm
- Fishbane S et al
Peginesatide in Patients with Anemia Undergoing Hemodialysis.
N Engl J Med 2013; 368:307-319January 24, 2013
PMID: 23343061
http://www.nejm.org/doi/full/10.1056/NEJMoa1203165
- Macdougall IC et al
Peginesatide for Anemia in Patients with Chronic Kidney Disease
Not Receiving Dialysis.
N Engl J Med 2013; 368:320-332January 24, 2013
PMID: 23343062
http://www.nejm.org/doi/full/10.1056/NEJMoa1203166
- Drueke TB
Anemia Treatment in Patients with Chronic Kidney Disease.
N Engl J Med 2013; 368:387-389January 24, 2013
PMID: 23343068
p://www.nejm.org/doi/full/10.1056/NEJMe1215043